Tarceva (erlotinib tablets - Genentech, generic) — Cigna
Non-Small Cell Lung Cancer (NSCLC)
Initial criteria
- Patient is age ≥ 18 years
- Patient has advanced or metastatic disease
- Patient has EGFR mutation-positive non-small cell lung cancer as detected by an approved test
Approval duration
1 year